Evidence of prolactin immunoreactivity in the bone marrow of untreated multiple myeloma patients

Klára Gadó, György Nagy, Ágnes Hasitz, B. Tóth, Èva Rimanóczi, Gyula Domján

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The role of prolactin (PRL) in the physiological regulation of the immune system and in hematopoiesis is well known. There is also evidence of the significance of PRL in several pathological conditions such as autoimmune diseases and some malignancies, e.g. colon and breast carcinomas and also B cell malignancies. Multiple myeloma is known as a B cell malignancy. It is the result of malignant transformation of a single clone of neoplastic plasma cells that synthesize abnormal amounts of monoclonal immunoglobulins or immunoglobulin fragments. In our present studies, the possible expression of PRL in bone marrow cells obtained from diagnosed multiple myeloma (17 cases) or nonmyeloma (5 cases) patients was examined by the method of immunocytochemistry. Samples obtained from those multiple myeloma patients (13 cases) who had not received chemotherapy for 6 months prior to these studies showed a positive immunocytochemical reaction for PRL. Bone marrow smears of patients diagnosed with multiple myeloma who had received chemotherapy within 6 months of the study and also the smears of patients without diagnosed multiple myeloma failed to show a positive immune reaction for PRL. In the case of a patient who was examined prior to and also after a period of 3 months of chemotherapy, the PRL-immunopositive bone marrow cells had disappeared due to the treatment. According to the light microscopic analysis of the cell morphology, PRL-immunopositive cells in the bone marrow were mainly, but not exclusively, plasma cells. There was no correlation between the positive PRL staining of cells and the type of monoclonal immunoglobulin or the ratio of plasma cells detected in the bone marrow. Taken together, our results indicate a possible role of PRL in multiple myeloma. Further experiments are necessary to identify the prognostic value of PRL in multiple myeloma.

Original languageEnglish
Pages (from-to)95-102
Number of pages8
JournalNeuroImmunoModulation
Volume9
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

Multiple Myeloma
Prolactin
Bone Marrow
Plasma Cells
Bone Marrow Cells
Drug Therapy
Immunoglobulins
B-Lymphocytes
Neoplasms
Immunoglobulin Fragments
Hematopoiesis
Autoimmune Diseases
Immune System
Colon
Clone Cells
Immunohistochemistry
Staining and Labeling
Breast Neoplasms
Light

Keywords

  • B cell malignancies
  • Human
  • Immunocytochemistry
  • Multiple myeloma
  • Prolactin

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)
  • Immunology

Cite this

Evidence of prolactin immunoreactivity in the bone marrow of untreated multiple myeloma patients. / Gadó, Klára; Nagy, György; Hasitz, Ágnes; Tóth, B.; Rimanóczi, Èva; Domján, Gyula.

In: NeuroImmunoModulation, Vol. 9, No. 2, 2001, p. 95-102.

Research output: Contribution to journalArticle

Gadó, Klára ; Nagy, György ; Hasitz, Ágnes ; Tóth, B. ; Rimanóczi, Èva ; Domján, Gyula. / Evidence of prolactin immunoreactivity in the bone marrow of untreated multiple myeloma patients. In: NeuroImmunoModulation. 2001 ; Vol. 9, No. 2. pp. 95-102.
@article{8ea7bdeefc504ca884a2627075a5dde6,
title = "Evidence of prolactin immunoreactivity in the bone marrow of untreated multiple myeloma patients",
abstract = "The role of prolactin (PRL) in the physiological regulation of the immune system and in hematopoiesis is well known. There is also evidence of the significance of PRL in several pathological conditions such as autoimmune diseases and some malignancies, e.g. colon and breast carcinomas and also B cell malignancies. Multiple myeloma is known as a B cell malignancy. It is the result of malignant transformation of a single clone of neoplastic plasma cells that synthesize abnormal amounts of monoclonal immunoglobulins or immunoglobulin fragments. In our present studies, the possible expression of PRL in bone marrow cells obtained from diagnosed multiple myeloma (17 cases) or nonmyeloma (5 cases) patients was examined by the method of immunocytochemistry. Samples obtained from those multiple myeloma patients (13 cases) who had not received chemotherapy for 6 months prior to these studies showed a positive immunocytochemical reaction for PRL. Bone marrow smears of patients diagnosed with multiple myeloma who had received chemotherapy within 6 months of the study and also the smears of patients without diagnosed multiple myeloma failed to show a positive immune reaction for PRL. In the case of a patient who was examined prior to and also after a period of 3 months of chemotherapy, the PRL-immunopositive bone marrow cells had disappeared due to the treatment. According to the light microscopic analysis of the cell morphology, PRL-immunopositive cells in the bone marrow were mainly, but not exclusively, plasma cells. There was no correlation between the positive PRL staining of cells and the type of monoclonal immunoglobulin or the ratio of plasma cells detected in the bone marrow. Taken together, our results indicate a possible role of PRL in multiple myeloma. Further experiments are necessary to identify the prognostic value of PRL in multiple myeloma.",
keywords = "B cell malignancies, Human, Immunocytochemistry, Multiple myeloma, Prolactin",
author = "Kl{\'a}ra Gad{\'o} and Gy{\"o}rgy Nagy and {\'A}gnes Hasitz and B. T{\'o}th and {\`E}va Riman{\'o}czi and Gyula Domj{\'a}n",
year = "2001",
doi = "10.1159/000049012",
language = "English",
volume = "9",
pages = "95--102",
journal = "NeuroImmunoModulation",
issn = "1021-7401",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Evidence of prolactin immunoreactivity in the bone marrow of untreated multiple myeloma patients

AU - Gadó, Klára

AU - Nagy, György

AU - Hasitz, Ágnes

AU - Tóth, B.

AU - Rimanóczi, Èva

AU - Domján, Gyula

PY - 2001

Y1 - 2001

N2 - The role of prolactin (PRL) in the physiological regulation of the immune system and in hematopoiesis is well known. There is also evidence of the significance of PRL in several pathological conditions such as autoimmune diseases and some malignancies, e.g. colon and breast carcinomas and also B cell malignancies. Multiple myeloma is known as a B cell malignancy. It is the result of malignant transformation of a single clone of neoplastic plasma cells that synthesize abnormal amounts of monoclonal immunoglobulins or immunoglobulin fragments. In our present studies, the possible expression of PRL in bone marrow cells obtained from diagnosed multiple myeloma (17 cases) or nonmyeloma (5 cases) patients was examined by the method of immunocytochemistry. Samples obtained from those multiple myeloma patients (13 cases) who had not received chemotherapy for 6 months prior to these studies showed a positive immunocytochemical reaction for PRL. Bone marrow smears of patients diagnosed with multiple myeloma who had received chemotherapy within 6 months of the study and also the smears of patients without diagnosed multiple myeloma failed to show a positive immune reaction for PRL. In the case of a patient who was examined prior to and also after a period of 3 months of chemotherapy, the PRL-immunopositive bone marrow cells had disappeared due to the treatment. According to the light microscopic analysis of the cell morphology, PRL-immunopositive cells in the bone marrow were mainly, but not exclusively, plasma cells. There was no correlation between the positive PRL staining of cells and the type of monoclonal immunoglobulin or the ratio of plasma cells detected in the bone marrow. Taken together, our results indicate a possible role of PRL in multiple myeloma. Further experiments are necessary to identify the prognostic value of PRL in multiple myeloma.

AB - The role of prolactin (PRL) in the physiological regulation of the immune system and in hematopoiesis is well known. There is also evidence of the significance of PRL in several pathological conditions such as autoimmune diseases and some malignancies, e.g. colon and breast carcinomas and also B cell malignancies. Multiple myeloma is known as a B cell malignancy. It is the result of malignant transformation of a single clone of neoplastic plasma cells that synthesize abnormal amounts of monoclonal immunoglobulins or immunoglobulin fragments. In our present studies, the possible expression of PRL in bone marrow cells obtained from diagnosed multiple myeloma (17 cases) or nonmyeloma (5 cases) patients was examined by the method of immunocytochemistry. Samples obtained from those multiple myeloma patients (13 cases) who had not received chemotherapy for 6 months prior to these studies showed a positive immunocytochemical reaction for PRL. Bone marrow smears of patients diagnosed with multiple myeloma who had received chemotherapy within 6 months of the study and also the smears of patients without diagnosed multiple myeloma failed to show a positive immune reaction for PRL. In the case of a patient who was examined prior to and also after a period of 3 months of chemotherapy, the PRL-immunopositive bone marrow cells had disappeared due to the treatment. According to the light microscopic analysis of the cell morphology, PRL-immunopositive cells in the bone marrow were mainly, but not exclusively, plasma cells. There was no correlation between the positive PRL staining of cells and the type of monoclonal immunoglobulin or the ratio of plasma cells detected in the bone marrow. Taken together, our results indicate a possible role of PRL in multiple myeloma. Further experiments are necessary to identify the prognostic value of PRL in multiple myeloma.

KW - B cell malignancies

KW - Human

KW - Immunocytochemistry

KW - Multiple myeloma

KW - Prolactin

UR - http://www.scopus.com/inward/record.url?scp=0034824261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034824261&partnerID=8YFLogxK

U2 - 10.1159/000049012

DO - 10.1159/000049012

M3 - Article

C2 - 11549891

AN - SCOPUS:0034824261

VL - 9

SP - 95

EP - 102

JO - NeuroImmunoModulation

JF - NeuroImmunoModulation

SN - 1021-7401

IS - 2

ER -